2024 Drug Development Protein Expression 
Alta Sciences
APRIL 17, 2024
Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.
Drug Target Review
SEPTEMBER 10, 2024
The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. Hence, in many cases an earlier IND may be prevented by the timely provision of representative Drug Substance (DS) to execute such toxicology studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Conversations in Drug Development Trends
MAY 30, 2024
This trend is on the rise despite recent disappointments with clinical trial outcomes, which have the potential to destabilize the industry in the short term regarding drug development strategy and optimal study designs. The shared placebo design is another approach to accelerating drug development in ALS research.
Drug Target Review
JANUARY 20, 2025
The oncology drug development landscape is evolving rapidly, driven by the deployment of targeted therapies in precision medicine and regulatory initiatives like the FDAs Project Optimus. It also covers strategies for drug developers who have yet to identify a biomarker, helping them advance their programs effectively.
FDA Law Blog: Drug Discovery
DECEMBER 6, 2024
Valentine On November 19, 2024, FDA released a draft guidance titled Frequently Asked Questions Developing Potential Cellular and Gene Therapy Products. Where vector presence is detected, transgene mRNA and/or protein expression levels should also be measured. Tobolowsky & Charles G. Raver & James E.
Expert insights. Personalized for you.
52 
Let's personalize your content